Athira Pharma, Inc. — FY2021 Form 10-K
Entity note: The request identifies Leonabio, Inc., but the supplied filing is for Athira Pharma, Inc. This summary reflects the filing provided. Reporting period: fiscal year ended December 31, 2021; filed March 28, 2022. This is an annual report, not a standalone Q4 report.
Business context
Athira is a clinical-stage biopharmaceutical company developing small molecules intended to enhance HGF/MET signaling and address neurological disorders. Its lead candidate, fosgonimeton (ATH-1017), is being studied for Alzheimer’s disease (AD); the company has no approved products and reported no product-sales revenue.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $42.8 million | $13.3 million |
| General and administrative expense | $21.2 million | $6.7 million |
| Total operating expenses | $64.0 million | $20.0 million |
| Grant income | $8.8 million | $1.3 million |
| Net loss | $54.9 million | $20.0 million |
| Basic and diluted loss per share | $1.49 | $1.67 |
| Net cash used in operating activities | $43.1 million | $24.1 million |
| Cash, cash equivalents and investments at year-end | $319.7 million | $268.2 million |
Operating expenses rose 220%, reflecting clinical and development activity, increased staffing and public-company, legal and insurance costs. The loss widened by $34.9 million year over year. Loss per share declined despite the larger net loss, primarily alongside a higher weighted-average share count after the 2020 IPO and 2021 follow-on offering. Margins are not meaningful because the company had no product revenue.
FY2021 cash flows included $97.1 million provided by financing, mainly from the follow-on offering, and $4.1 million used in investing. Year-end total assets were $332.0 million; total liabilities were $10.9 million, primarily operating lease liabilities and accrued liabilities. The filing reports no outstanding debt at year-end; convertible notes had converted in 2020. Management estimated available cash and investments would fund operations and capital needs through at least the next 12 months following the filing date, while another passage describes funding at least through 2022. No clear quarterly cash-burn or runway breakdown is provided.
Clinical progress, outlook and key risks
- Fosgonimeton: LIFT-AD, a Phase 2/3 trial in mild-to-moderate AD, was planned to enroll 420 participants after a January 2022 increase from 300 to strengthen power for co-key secondary endpoints. Topline results were expected in the first half of 2023. ACT-AD enrollment was completed in October 2021; topline results were expected in the second quarter of 2022. These are forward-looking expectations in the filing, not reported results.
- Other programs: A Phase 2 proof-of-concept trial for Parkinson’s disease dementia and dementia with Lewy bodies began at the end of 2021, with the first patient dosed in January 2022. ATH-1020’s IND was accepted in January 2022 and its Phase 1 study began in Q1 2022. ATH-1019 remained in discovery/development for peripheral indications.
- Early evidence and uncertainty: In a Phase 1a/b study of 88 subjects, including only 11 with AD, fosgonimeton was reported as well tolerated without serious adverse events. P300 latency improved in the small AD group, but the company explicitly stated it had not established that this measure translated into improved cognition. Small early trials may not predict pivotal-trial outcomes.
- Funding and execution: Athira anticipated continued losses and substantial additional funding needs. Clinical delays, enrollment and retention, COVID-19 impacts, third-party research/manufacturing dependence, regulatory approval, competition and reimbursement are significant risks.
- Research-integrity and legal matters: A board special committee found that former CEO Leen Kawas altered images in her dissertation and at least four co-authored papers; WSU’s separate review was ongoing. The company disclosed potential consequences for reputation, its WSU-licensed dihexa intellectual property and grants. Consolidated securities class-action litigation related to alleged omissions was pending; the company reported it could not estimate a possible loss and recorded no liability. An activist stockholder had announced a planned proxy contest.
- Leadership and control: Kawas resigned as CEO and director in October 2021; Mark Litton became CEO. Management concluded disclosure controls and internal control over financial reporting were effective at year-end. The auditor issued an unqualified opinion on the financial statements but did not attest to internal control, under the emerging-growth-company exemption.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Athira Pharma, not Leonabio.
- Check subsequent disclosures for ACT-AD and LIFT-AD results, regulatory feedback and any changes to trial design, enrollment or timelines.
- Track WSU’s research-misconduct review and any effects on the licensed patents, grants or development programs.
- Review updates on securities litigation, the proxy contest and related costs or outcomes.
- Assess cash use and funding needs against the stated runway estimate, including the impact of ongoing trials and legal expenses.
- Verify the status and commercial relevance of Athira’s patent portfolio and the terms of the WSU license.